Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch | Ausblick |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99.39 |
PRIMECAP Management Co. | 11.06 |
PRIMECAP Management Co. | 10.88 |
Vanguard Group, Inc. (Subfiler) | 8.00 |
The Vanguard Group, Inc. | 7.97 |
Vanguard PRIMECAP Fund | 6.23 |
State Street Corp. | 4.74 |
Wellington Management Co. LLP | 3.71 |
BlackRock Fund Advisors | 3.43 |
T. Rowe Price Investment Management, Inc. | 3.28 |
Vanguard Health Care Fund | 3.15 |
Vanguard Total Stock Market ETF | 3.13 |
Vanguard 500 Index Fund | 2.42 |
JPMorgan Investment Management, Inc. | 2.41 |
Geode Capital Management LLC | 2.24 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 7'800 | 7'400 | 9'100 | 9'610 | 8'725 |
Umsatz pro Mitarbeiter in Mio. EUR | 1.55 | 1.72 | 1.36 | 1.08 | 1.08 |
Bilanz (in Mio. EUR) - Aktiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 7'641 | 8'382 | 6'887 | 7'857 | 9'791 |
Summe Anlagevermögen | 18'976 | 19'784 | 18'612 | 18'589 | 20'109 |
Summe Aktiva | 25'289 | 27'234 | 24'619 | 23'877 | 24'554 |
Bilanz (in Mio. EUR) - Passiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 5'937 | 6'441 | 7'911 | 7'693 | 6'711 |
Summe Fremdkapital | 12'257 | 13'895 | 13'933 | 12'918 | 11'166 |
Summe Eigenkapital | 13'032 | 13'339 | 10'686 | 10'960 | 13'388 |
Summe Passiva | 25'289 | 27'234 | 24'619 | 23'877 | 24'554 |
Adresse
225 Binney Street, 02142 Cambridge | |
Telefon | +1 (617) 679-2000 |
URL | http://www.biogen.com |
Management
Adam Keeney
Executive VP & Head-Corporate Development |
Anabella Villalobos
SVP-Biotherapeutic & Medicinal Sciences |
Ann E. Beasley
Chief Compliance Officer & Senior Vice President |
Caroline D. Dorsa
Chairman |
Christopher A. Viehbacher
President, Chief Executive Officer & Director |
Chuck Triano
Senior Vice President |
Eric K. Rowinsky
Independent Director |
Ginger Gregory
Chief Human Resources Officer & Executive VP |
Jake Elkins
Vice President & Head-Acute Neurology Research |
Jane Grogan
Executive Vice President & Head-Research |
Jesus B. Mantas
Independent Director |
Mahalakshmi Radhakrishnan
Chief Medical Officer & Group Senior VP |
Maria C. Freire
Independent Director |
Michael E. Dambach
Treasurer & Vice President |
Michael Hencke
Executive Director-Investor Relations |
Michael R. McDonnell
Chief Financial Officer & Executive Vice President |
Nicole Murphy
Head-Pharmaceutical Operations & Technology |
Priya Singhal
Executive Vice President & Head-Development |
Rachid Izzar
Executive Vice President |
Robert Kilo
Account Director |
Robin C. Kramer
Chief Accounting Officer & Senior Vice President |
Rohin Mhatre
Senior VP-Product & Technology Development |
Stephen A. Sherwin
Independent Director |
Susan H. Alexander
Secretary, Chief Legal Officer & Executive VP |
Susan Langer
Independent Director |
Wendell C. Taylor
Chief Corporation Counsel & Assistant Secretary |
William A. Hawkins
Independent Director |